Clinical Trials Logo

Clinical Trial Summary

This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has spread to other places in the body (advanced). Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether IMRT is more effective with or without cisplatin in treating patients with oropharyngeal cancer.


Clinical Trial Description

PRIMARY OBJECTIVES: -To select the arm(s) achieving a 2-year progression-free survival rate of >= 85% without unacceptable swallowing toxicity at 1 year. SECONDARY OBJECTIVES: - To determine patterns of failure (locoregional relapse versus distant) and survival -(overall and progression-free) at 6 months and 2 years. - To determine acute toxicity profiles at the end of radiation therapy and at 1 and 6 months. - To determine late toxicity profiles at 1 and 2 years. - To determine patient-reported swallowing outcomes at 6 months and 1 and 2 years. - To determine the predictive value of 12-14 week, post-treatment fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) for locoregional control and progression free survival (PFS) at 2 years. - To determine the predictive value of blood and tissue biomarkers for disease outcomes at 2 years. - To determine swallowing recovery per videofluoroscopy imaging at 2 years. After completion of study treatment, patients are followed at 1 and 3 months then every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02254278
Study type Interventional
Source NRG Oncology
Contact
Status Active, not recruiting
Phase Phase 2
Start date October 2014
Completion date May 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT01932697 - Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer Phase 2
Completed NCT01256385 - Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Phase 2
Completed NCT03342911 - Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Phase 2
Completed NCT03032250 - Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer N/A
Terminated NCT02388932 - Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer N/A
Terminated NCT02196168 - Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Active, not recruiting NCT02007200 - Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Phase 2
Completed NCT02827838 - Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Phase 2
Completed NCT03422536 - Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma Phase 2
Terminated NCT02334319 - Ganetespib Window of Opportunity Study in Head and Neck Cancers Phase 1
Active, not recruiting NCT01267240 - Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Phase 2